Visit Our Blog
  • About FDNA
  • Products
    • Face2Gene Clinic
    • Face2Gene Labs
  • Contact
  • Blog
  • News & Publications
  • Blog

Categories
  • All
  • ACMG
  • Case Study
  • Diagnostic odyssey
  • Events/Conferences
  • Face2Gene
  • Geneticist profile
  • Genomics
  • Phenotyping
  • Rare Diseases
  • Scientific Abstracts
  • Talks
  • Technology
  • Uncategorized
  • Videos

“Where are the limits?”

July 9, 2018

By FDNA Team

Talks

Big data, next-generation phenotyping, and the possibilities for precision medicine

This post is based on a presentation given at the Precision Medicine World Conference. You can skip to the video by clicking here.

As researchers and clinicians expand their investigation of the relationship between phenotypes and genotypes, the importance of accurate phenotypic analysis grows. That means the field needs a uniform understanding of what phenotypes are, how to describe them, and how to assign traits.

In differentiating deep phenotyping and next-generation phenotyping, Dr. Donald Basel (Medical Director of the Genetics Center at the Children’s Hospital of Wisconsin) asked Precision Medicine World Conference attendees, “Where do we limit our thoughts as to what a phenotype represents? Is it limited to structural morphology or do we consider all aspects of the phenotype?”

Deep phenotyping, which has existed since the 1950s, made a leap forward in dysmorphology when in 2009 NHGRI developed a common language, the hierarchical Human Phenotype Ontology (HPO). Next-generation phenotyping expands that concept, including not just structural morphology but aspects like speech analysis, gait analysis, and all of the “omics”–metabolomics, microbiomics, etc.

Even with the benefits of a common language, clinicians are still faced with the challenge of properly applying the HPO terms. Dr. Basel (also a member of the FDNA Scientific Advisory Board) noted that a tool like Face2Gene, a suite of phenotyping applications, does some of this identification for the clinician, and gave an example of human vs machine analysis of Cornelia de Lange syndrome and phenotypically similar syndromes. A panel of experts identified patients with Cornelia de Lange 77 percent of the time and spotted the similar syndromes 87 percent of the time, with a clinical sensitivity of 82 percent and a specificity of 89 percent, whereas FDNA’s DeepGestalt technology correctly selected Cornelia de Lange 94 percent of the time and similar phenotypes 100 percent of the time, with a sensitivity of 86 percent and a specificity of 100 percent.

Of course, as Dr. Basel pointed out, when it comes to Cornelia de Lange, a well-trained dysmorphologist can “essentially walk into a baby’s room and make this diagnosis.” The more profound results are for patients with phenotypes that would be far more difficult to diagnose because of the subtlety of facial traits, or for helping non-dysmorphologists recognize these phenotypes.

In a March 2018 publication Dr. Basel described as “quite daring,” researchers took four syndromes with inborn metabolic errors and mild facial feature coarsening, plus Nicolaides-Baraitser syndrome (which has a similar phenotype) to test the

“Just looking at pure facial imaging the software was able to accurately predict the specific disorder in 64 percent of the cases. If you added a single feature into that feature set, the diagnostic accuracy increased to 87 percent.”

This means clinicians using Face2Gene may be presented with syndrome recommendations that they might have otherwise disregarded.

Similarly to how clinicians gain expertise with practice, Face2Gene grows smarter as it sees more cases. “The more we use it, the better it gets,” Basel said.

Which brought him back to his original question: if artificial intelligence technologies can grow to analyze more and more data of increasingly varied types, “Where are the limits?”

 

Donald Basel presents at PMWC

More entries about Talks

TalksTechnology
 

Webinar: Matching ultra-rare cases in the clinic

Check out now the recording of the webinar that took place on June 3rd, 2022 about matching ultra-rare cases in Read more

Talks
 

Personalizing Medicine with Artificial Intelligence and Facial Analysis

Personalizing Medicine with Artificial Intelligence and Facial Analysis Presented by Omar Abdul-Rahman, MD, University of Nebraska Medical Center Precision Medicine Read more

Face2GeneTalksVideos
 

The Genomics Collaborative: How to Design the Future of Health—Together

  ThinkGenetic recently hosted a panel discussion among researchers involved in the Genomics Collaborative, an FDNA initiative connecting researchers, clinicians, Read more

Events/Conferences
 

AI in Healthcare: Separating the Hype from the Hope

FDNA’s CEO Dekel Gelbman recently spoke to hundreds of leaders during the Stanford Big Data in Precision Health Summit. The Read more

Talks
 

“Where are the limits?”

Big data, next-generation phenotyping, and the possibilities for precision medicine This post is based on a presentation given at the Read more

Events/Conferences
 

FDNA and Face2Gene Featured at ESHG

  A flock of researchers from around the globe shared their findings in dysmorphology and molecular genetics at this year’s Read more

ACMG
 

Dr. Christine Stanley: Face2Gene LABS at WuXi NextCODE: Phenotyping for Improved Variant Prioritization

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> Read more

ACMG
 

Dr. John Carey: Delineating Genetic Syndromes and Next-Generation Phenotyping

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

ACMG
 

Dr. Karen Gripp: Face2Gene RESEARCH for Deep Phenotyping of Novel Syndromes

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

Events/ConferencesFace2GeneTalks
 

FDNA’s Keynote at ePharma: Using Next-Generation Phenotyping For Precision Medicine Across the Pharma Value Chain

NOTE: This post is based on a presentation made at the March 2018 ePharma conference in New York City.   Read more

Face2Gene
 

Redefining Phenotyping for Clinical Advancements and Variant Prioritization

FDNA’s CEO, Dekel Gelbman, joined two distinguished members of the genetics community—Dr. John Carey (University of Utah) and Dr. Christine Read more

  • Contact Us
  • Privacy Policy
  • Terms of Use

Signup for News


* These fields are required.

© 2011-2022 FDNA INC. www.FDNA.com. All rights reserved.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.